A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Phase 2/3
210
about 1.7 years
18–75
31 sites in AZ, CA, FL +15
Why this study is shown
What this study is about
Researchers are testing whether BFB759, a biological treatment, is effective and safe compared to a placebo for people with moderate to severe hidradenitis suppurativa. The trial will last approximately 36 to 40 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo for BFB759
- 2.Receive BFB759
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Evaluate the safety/tolerability of BFB759, To evaluate the clinical activity of BFB759 using the Skin Pain Numerical Rating Scale (NRS)